Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafluprost

FDA-approved product (solution/drops, ophthalmic), marketed as Tafluprost, Zioptan.

Registered studies
37
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tafluprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

37registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafluprost in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafluprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

    NCT02471105 · start 2015-09

    Registered record
    Registry ID
    NCT02471105
    Conditions
    Ocular Hypertension; Glaucoma
    Interventions
    Preserved Bimatoprost 0.01%; Tafluprost Unit Dose Preservative Free 15microgram/ml
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-09
    Completion
    2017-12
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Glaucoma
    InterventionPreserved Bimatoprost 0.01%; Tafluprost Unit Dose Preservative Free 15microgram/ml
    PhasePhase 4
    Registry statusUnknown

  • 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

    NCT02802137 · start 2015-03

    Registered record
    Registry ID
    NCT02802137
    Conditions
    Glaucoma; Ocular Surface Disease
    Interventions
    tafluprost; tafluprost and dorzolamide/timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-03
    Completion
    2016-01
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Surface Disease
    Interventiontafluprost; tafluprost and dorzolamide/timolol
    PhasePhase 4
    Registry statusCompleted

  • The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

    NCT01927406 · start 2014-06

    Registered record
    Registry ID
    NCT01927406
    Conditions
    Thyroid Eye Disease; Ocular Hypertension; Glaucoma
    Interventions
    Prostaglandin Analog; Timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2014-06
    Completion
    2016-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Eye Disease; Ocular Hypertension; Glaucoma
    InterventionProstaglandin Analog; Timolol
    PhasePhase 4
    Registry statusWithdrawn

  • A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

    NCT02102750 · start 2014-06

    Registered record
    Registry ID
    NCT02102750
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Preservative free tafluprost opthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-06
    Completion
    2017-07-03
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionPreservative free tafluprost opthalmic solution
    PhasePhase 1
    Registry statusCompleted

  • An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More

    NCT01979913 · start 2013-10

    Registered record
    Registry ID
    NCT01979913
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension
    InterventionSaflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

    NCT03104621 · start 2013-03

    Registered record
    Registry ID
    NCT03104621
    Conditions
    Primary Open-angle Glaucoma
    Interventions
    Benzalkonium chloride (BAK); 0.0015% tafluprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-03
    Completion
    2015-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open-angle Glaucoma
    InterventionBenzalkonium chloride (BAK); 0.0015% tafluprost
    PhasePhase 4
    Registry statusCompleted

  • A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

    NCT01654484 · start 2012-07

    Registered record
    Registry ID
    NCT01654484
    Conditions
    Glaucoma and Ocular Hypertension
    Interventions
    DE-117; 0.0015% tafluprost; DE-117 and 0.0015% tafluprost; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma and Ocular Hypertension
    InterventionDE-117; 0.0015% tafluprost; DE-117 and 0.0015% tafluprost; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Switching From Preserved to Preserved-free Treatments for Glaucoma.

    NCT01433900 · start 2012-05

    Registered record
    Registry ID
    NCT01433900
    Conditions
    Glaucoma
    Interventions
    Tafluprost; Latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2012-05
    Completion
    2014-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTafluprost; Latanoprost
    PhasePhase 3
    Registry statusUnknown

  • Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)

    NCT01254604 · start 2011-12-01

    Registered record
    Registry ID
    NCT01254604
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Preservative-Free Tafluprost or vehicle; Preservative-Free Timolol maleate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12-01
    Completion
    2013-05-09
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionPreservative-Free Tafluprost or vehicle; Preservative-Free Timolol maleate
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops

    NCT01434888 · start 2011-09

    Registered record
    Registry ID
    NCT01434888
    Conditions
    Healthy Volunteers
    Interventions
    Preservative free tafluprost 0.0015% eye drops; Preservative free timolol 0.5% eye drops; Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2011-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionPreservative free tafluprost 0.0015% eye drops; Preservative free timolol 0.5% eye drops; Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops
    PhasePhase 1
    Registry statusCompleted

  • DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

    NCT01342081 · start 2011-05

    Registered record
    Registry ID
    NCT01342081
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    DE-111 ophthalmic solution; Tafluprost ophthalmic solution 0.0015%; Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    Not recorded
    Enrolment
    489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionDE-111 ophthalmic solution; Tafluprost ophthalmic solution 0.0015%; Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
    PhasePhase 3
    Registry statusCompleted

  • Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)

    NCT01162603 · start 2011-03

    Registered record
    Registry ID
    NCT01162603
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Goldmann and Perkins applanation tonometry; TAFLUPROST 0.0015% EYEDROPS; LATANOPROST 0.005% EYEDROPS
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension
    InterventionGoldmann and Perkins applanation tonometry; TAFLUPROST 0.0015% EYEDROPS; LATANOPROST 0.005% EYEDROPS
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy

    NCT01263444 · start 2011-03

    Registered record
    Registry ID
    NCT01263444
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 1% / timolol 0.5% Fixed Combination; Habitual prostaglandin monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2013-04
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionBrinzolamide 1% / timolol 0.5% Fixed Combination; Habitual prostaglandin monotherapy
    PhasePhase 4
    Registry statusCompleted

  • Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

    NCT01306461 · start 2011-03

    Registered record
    Registry ID
    NCT01306461
    Conditions
    Ocular Hypertension; Open-angle Glaucoma
    Interventions
    Timolol and Tafluprost; Fixed Dose Combination of tafluprost and timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-05
    Enrolment
    401

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open-angle Glaucoma
    InterventionTimolol and Tafluprost; Fixed Dose Combination of tafluprost and timolol
    PhasePhase 3
    Registry statusCompleted

  • Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies

    NCT01292460 · start 2011-02

    Registered record
    Registry ID
    NCT01292460
    Conditions
    Ocular Hypertension; Open-angle Glaucoma
    Interventions
    Timolol/ FDC/ Placebo/ Tafluprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-02
    Completion
    2012-09
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open-angle Glaucoma
    InterventionTimolol/ FDC/ Placebo/ Tafluprost
    PhasePhase 3
    Registry statusCompleted